Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Living Cell Technologies ( (AU:1AI) ) has shared an update.
Algorae Pharmaceuticals has disclosed a change in director David Hainsworth’s interests in the company’s securities following his participation in a loyalty option offer. Hainsworth, who holds both direct and indirect stakes, acquired a total of 5,125,000 new unlisted options exercisable at $0.014 and expiring on 1 December 2029, at an issue price of $0.001 per option, increasing his exposure to the company’s equity without disposing of any existing securities, which further aligns his incentives with long‑term shareholder value.
More about Living Cell Technologies
Algorae Pharmaceuticals Limited is an Australian-listed pharmaceutical company, focused on developing therapeutics, with its securities traded on the ASX. The company’s capital structure includes ordinary shares, performance rights and various classes of options, and it engages with shareholders through mechanisms such as loyalty option offers to support ongoing funding and alignment of management with investor interests.
YTD Price Performance: 50.0%
Average Trading Volume: 3,168,696
Technical Sentiment Signal: Buy
Current Market Cap: A$25.33M
Find detailed analytics on 1AI stock on TipRanks’ Stock Analysis page.